Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation
27/05/2026 15:35
BRIEF-FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation May 27 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O:
FDA APPROVES USE OF LINZESS® (LINACLOTIDE) IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER WITH FUNCTIONAL CONSTIPATION (FC)
IRONWOOD PHARMACEUTICALS - LINZESS CONTRAINDICATED IN PATIENTS UNDER 2 YEARS DUE TO RISK OF SERIOUS DEHYDRATION
IRONWOOD PHARMACEUTICALS INC: LINZESS IS CONTRAINDICATED IN PATIENTS WITH KNOWN OR SUSPECTED MECHANICAL GASTROINTESTINAL OBSTRUCTION
Source text: ID:nBw81Zz0ra
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation